European filing of Seebri Breezhaler triggers $5m from Novartis for Vectura
This article was originally published in Scrip
Executive Summary
Novartis has filed for marketing authorisation from the European Medicines Agency for the inhaled long-acting muscarinic receptor antagonist (LAMA), NVA237 (glycopyrronium bromide; brand name of Seebri Breezhaler), for the treatment of chronic obstructive pulmonary disease (COPD).